# US 2023/0399627 A1 · Vector genetically engineered with chimeric antigen receptor and against two or more targets and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399627 A1
- Document ID: US20230399627A1
- Status: Published application
- Kind: A1
- Application number: 18/251,264
- Filed: 2021-11-02
- Published: 2023-12-14
- Earliest claimed: 2020-11-02
- Assignees: Sph Biotherapeutics (Shanghai) Limited.
- Applicants: Sph Biotherapeutics (Shanghai) Limited.
- Inventors: Benshang LI; Tianyi WANG; Xinyu WAN; Xiaomin YANG
- Web page: https://patentgrep.com/patent/US20230399627A1

## CPC

- C12N 5/10: Cells modified by introduction of foreign genetic material
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4212: {CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2}
- A61K 40/4221: {CD20}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/16032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are a vector genetically engineered with a chimeric antigen receptor and against two or more targets for combined treatment of disease such as human tumors, a related immune cell and application thereof. The vector genetically engineered with a chimeric antigen receptor and the related immune cell have enhanced ability to kill target cells.

## Claims

### Claim 1

A nucleic acid molecule expressing at least two types of chimeric antigen receptors (CAR), comprising a nucleic sequence encoding a leader peptide, a nucleic acid sequence encoding a first antigen-binding domain, a nucleic sequence encoding a first non-antigen binding function domain, a nucleic sequence encoding a cleavable peptide, a nucleic sequence encoding a leader sequence, a nucleic acid sequence encoding a second antigen-binding domain, and a nucleic sequence encoding a first non-antigen binding function domain;
wherein said non-antigen binding function domain comprises a hinge region, a transmembrane region, a co-stimulatory domain and an intracellular signaling domain,
wherein the hinge region and transmembrane region of said first non-antigen binding function domain are derived from CD28 hinge region and CD28 transmembrane region, the hinge region and transmembrane region of said second non-antigen binding function domain are derived from CD8 hinge region and CD8 transmembrane region.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said antigen-binding domains specifically bind to tumor antigens, and said tumor antigens are selected from the group consisting of: A33, B7H3, BCMA, CA125, CD1, CD10, CD102, CD11a, CD11b, CD123, CD13, CD133, CD134, CD137, CD138, CD14, CD15, CD19, CD2, CD20, CD200, CD21, CD22, CD23, CD25, CD27, CD28, CD3, CD30, CD33, CD34, CD36, CD37, CD38, CD4, CD40, CD41, CD42, CD43, CD44, CD45, CD5, CD56, CD58, CD65, CD66c, CD7, CD70 CD73, CD74, CD8, CD80, CD81, CD86, CD9, CD94, CD97, CD99, CEA, CEACAM6, CLL1, CS1, DLL1, DLL3, EGFR, EGFR VIII, ERBB2, FGF19, GD2, GD3, HER3, IL3Ra, NCAM, NG2, NKG2A, NTBA, PD-1, PDL-1, PSGL1, PSMA, ROR1, and VEGF.

### Claim 5 (depends on 1)

The nucleic acid molecule according to claim 1, comprising a nucleic acid sequence encoding a promoter.

### Claim 6 (depends on 5)

The nucleic acid molecule according to claim 5, wherein said promoter is selected from the group consisting of: EF1α, CMV, MSCV, and UbC.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said leader peptide comprises a leader peptide moiety derived from a protein selected from the group consisting of CD8, CD33, and CD45.

### Claim at position 10

10-13. (canceled)

### Claim 14 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said co-stimulatory domain comprises a co-stimulatory domain derived from a protein selected from the group consisting of: 4-1BB OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1, and ICOS.

### Claim 15 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said intracellular signaling domain comprises an intracellular signaling domain derived from a protein selected from the group consisting of: CD3ζ, FccRIγ, and ZAP70.

### Claim 16 (depends on 1)

The nucleic acid molecule according to claim 1, comprising a nucleic acid sequence encoding WPRE, wherein said nucleic acid sequence encoding WPRE is located downstream of said nucleic acid sequence encoding the non-antigen-binding function domain.

### Claim 17 (depends on 1)

The nucleic acid molecule according to claim 1, comprising a nucleic acid sequence encoding a backbone vector, wherein said nucleic acid sequence encoding the backbone vector is located upstream of said nucleic acid sequence encoding the promoter.

### Claim 18 (depends on 17)

The nucleic acid molecule according to claim 17, wherein said backbone vector comprises a viral vector.

### Claim 19 (depends on 17)

The nucleic acid molecule according to claim 17, wherein said backbone vector comprises an HIV packaging vector.

### Claim 20 (depends on 1)

The nucleic acid molecule according to claim 1, comprising a 5′ LTR sequence located at a 5′-terminal of said nucleic acid molecule, and a 3′ LTR sequence located at a 3′-terminal of said nucleic acid molecule.

### Claim at position 18

21-25. (canceled)

### Claim 26 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said cleavable peptide is selected from the group consisting of: P2A, T2A, F2A, E2A, BmCPV2A, and BmIFV2A.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The nucleic acid molecule according to claim 1, which expresses two types of chimeric antigen receptors.

### Claim at position 24

31-41. (canceled)

### Claim 42 (depends on 1)

The nucleic acid molecule according to claim 1, comprising a nucleotide sequence as set forth in any one of SEQ ID NO: 83 or SEQ ID NO: 84.

### Claim 43 (depends on 1)

A plasmid, comprising the nucleic acid molecule of claim 1.

### Claim 44 (depends on 43)

The plasmid according to claim 43, comprising a viral plasmid.

### Claim 45 (depends on 1)

A cell, comprising the nucleic acid molecule of claim 1.

### Claim 46 (depends on 45)

The cell according to claim 45, comprising a cell selected from the group consisting of: a T cell and a NK cell.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

An application of the nucleic acid molecule of claim 1 in preparation of chimeric antigen receptors.

### Claim at position 32

49-95. (canceled)
